INTRODUCTION {#s1}
============

Clear cell renal cell carcinoma (ccRCC) is the most common RCC subtype, and alterations of chromatin remodelers (*BAP1*, *PBRM1*, and *SETD2*) on chromosome 3p occur in 50% of ccRCCs.^[@B1]-[@B4]^ Our group identified that expression of these chromatin remodelers defines subgroups with divergent clinical outcomes.^[@B3],[@B4]^ Building on these observations, investigators have identified enhancer of zeste homolog 2 (EZH2) expression as a prognostic factor in ccRCC. Unfortunately, studies evaluating the association of EZH2 and RCC outcomes have reported conflicting results, with higher EZH2 expression being associated with a lower risk of recurrence in one study,^[@B5]^ whereas the other study indicates an association with higher risk of death.^[@B5],[@B6]^ Improved understanding of this putative association has important clinical implications. Validated prognostic models (eg, the Mayo Clinic stage, size, grade, and necrosis \[SSIGN\] score) and adjuvant therapy trials do not incorporate any molecular biomarkers. Even patients with low-risk disease as defined by these clinical algorithms can experience cancer recurrence.^[@B7],[@B8]^ Indeed, despite adherence to surveillance guidelines after surgery, roughly one-third of primary ccRCC recurrences experience disease progression, indicating a clinical need to better identify those patients with RCC with a high risk of death, particularly those mischaracterized as low risk by current prognostic algorithms or with small renal tumors (≤ 4 cm).^[@B9]^

Motivated by these clinical needs in ccRCC and the conflicting data from two studies, we evaluated the association in three independent cohorts. First, we evaluated *EZH2* mRNA expression and overall survival in The Cancer Genome Atlas cohort (TCGA; n = 532). Second, we performed an immunohistochemistry (IHC) assay for EZH2 that is compatible with formalin-fixed, paraffin-embedded (FFPE) tissue to evaluate the association of EZH2 protein expression and overall death in a pilot cohort of patients (n = 122) at the University of Texas Southwestern Medical Center (UTSW). Finally, we validated our findings in an independent cohort of patients at Mayo Clinic (n = 1,338). From all of these analyses, we validated that increased tumor-based EZH2 expression is associated with a higher risk of overall death for patients undergoing surgery for ccRCC. We also provide the first evidence, to our knowledge, that this association remains for cancer-specific survival and among the clinically important subset of patients with ccRCC classified as low and intermediate risk by the SSIGN score.

METHODS {#s2}
=======

UTSW Patient Selection and Study Design (analytic cohort) {#s3}
---------------------------------------------------------

The analytic cohort included a previously described set of 122 patients who underwent resection for ccRCC at UTSW with clinical data for age, sex, tumor grade, histology, and clinical outcomes.^[@B10],[@B11]^ Exclusion criteria included patients receiving neoadjuvant systemic therapies. Institutional review board approval was obtained at UTSW. Dates of death were obtained from the electronic medical records and Social Security Death Index. Twenty-four patients (19.7%) were deceased, and the follow-up was 5.8 years (range, 0.0 to 15.7 years). One patient was missing data.

To standardize the cases for clinicopathologic variables, a genitourinary pathologist (P.K.) reviewed all of the tumors. A tissue microarray^[@B12]^ was generated with two to five, 1.0-mm punches to represent different morphologic patterns from each tumor.

Mayo Clinic Patient Selection and Study Design (validation cohort) {#s4}
------------------------------------------------------------------

Inclusion criteria included patients who underwent resection for ccRCC with data for age, sex, tumor grade, histology, and clinical outcomes. Exclusion criteria included patients receiving neoadjuvant systemic therapies. Institutional review board approval was obtained at Mayo Clinic. We identified 1,360 patients who underwent resection for ccRCC between 1990 and 2009. Overall and RCC-specific death data were obtained from the Mayo Clinic Nephrectomy Registry. For RCC-specific survival, if the death was in a prior year, the death certificate was reviewed to determine the cause of death. In the event that the certificate was uninformative, correspondence with the patient's local physician and/or family occurred to determine cause of death. Two hundred sixty patients (19.4%) were deceased, and the median follow-up among patients who were alive was 8.8 years (range, 0.01 to 21.1 years).

To standardize the cases, a genitourinary pathologist (J.C.) reviewed all of the cases and selected an FFPE tumor block with the highest tumor content and Fuhrman grade. The median FFPE block age was 14.4 years (range, 8.1 to 26.3 years).

EZH2 Protein Expression {#s5}
-----------------------

Antigen retrieval and IHC staining were performed using a Dako Autostainer Link 48 (Agilent, Santa Clara, CA) with EnVision FLEX Target Retrieval Solution. Appropriate controls (positive and negative) were used with each run of immunostaining. The EZH2 monoclonal antibody (Ventana SP129, Spring Bioscience, CA; 1:2,500) is directed against human EZH2 expressed in human cancer cells.^[@B13],[@B14]^ Infiltrating reactive lymphocytes served as internal positive controls.

Evaluation of EZH2 IHC Intensity by Visual and Digital (Aperio) Scoring {#s6}
-----------------------------------------------------------------------

For pathologist visual scoring, two different manual methods were compared. A genitourinary pathologist (P.K.) measured the average percentage of cells staining across the entire slide and the average percentage of cells staining in any single ×10 hot spot field. For digital image analysis, slides were scanned using an Aperio ScanScope AT Turbo and reviewed using the eSlide Manager (version 12.0.0.5040) and ImageScope (version 12.1.0.5029) systems (Leica Biosystems, Melbourne, Australia). The GENIE (version 11.2) histomorphology image analysis tool was trained to annotate tumor areas. Representative tumor regions were manually selected (tumor necrosis areas were avoided) to exclude regions where GENIE inadequately identified tumor cells. The GENIE Nuclear Algorithm (version 11.2) was used to select tumor areas for quantitative analysis, yielding a percentage of tumor nuclei positive for EZH2.

Statistical Analyses {#s7}
--------------------

To assess categorical variables across groups, the χ^2^ or Fisher's exact test was used, and continuous variables were analyzed via Wilcoxon rank-sum or Kruskal-Wallis test. To assess the association of EZH2 expression with outcome, Cox proportional hazards models were used. Cox model assumptions were evaluated by assessing the parallel alignment of the log-log survival curves; no violation was observed. Overall survival was calculated from time of surgery to death as a result of any cause. Cancer-specific survival was calculated from time of surgery to RCC-related death; patients were censored if they were lost to follow-up or died of other causes. Time-dependent receiver operating characteristic curves were used to evaluate prognostic performance; the area under the curve (AUC) was calculated at 1, 2, 5, 10, and 15 years of follow-up.

To dichotomize mRNA and protein expression, a cut point was chosen that maximized the concordance index (C-index). In doing so, for *EZH2* mRNA expression in the TCGA cohort, tumors with \> 5.36 and ≤ 5.36 (expectation-maximization normalized counts) were categorized as having high and low expression, respectively. For the UTSW cohort, tumors with \> 8.0% and ≤ 8.0% EZH2-positive nuclei were categorized as having high and low expression, respectively. For the Mayo cohort, tumors with \> 8.7% and ≤ 8.7% EZH2-positive nuclei were categorized as having high and low expression, respectively. To assess predictive ability, bootstrap methodology was used to obtain optimism-corrected estimates of the C-index.^[@B15]^ Statistical analyses were performed using R (version 3.2.3). *P* values \< .05 were considered statistically significant.

RESULTS {#s8}
=======

Association of EZH2 mRNA Expression With Overall Survival in TCGA ccRCC Data Set {#s9}
--------------------------------------------------------------------------------

In the TCGA cohort, 65% of patients were male, the median age was 61 years, and the median tumor size was 5.5 cm ([Table 1](#T1){ref-type="table"}). Continuous *EZH2* expression was significantly associated with overall survival after adjusting for age (hazard ratio \[HR\], 2.26; 95% CI, 1.69 to 3.02; *P* \< .001; [Table 2](#T2){ref-type="table"}). When modeled as a dichotomized variable, patients with *EZH2*-high mRNA expression were 2.56 times more likely to experience death than patients with *EZH2*-low expression (95% CI, 1.85 to 3.54; *P* \< .001). After adjustment for age and SSIGN, patients with *EZH2*-high mRNA expression were 1.54 times more likely to experience death than patients with *EZH2*-low expression (95% CI, 1.05 to 2.27; *P* = .028). The association of age and SSIGN with survival is provided in Appendix [Table A1](#TA.1){ref-type="table"} (online only).
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Clinical Characteristics of TCGA, UTSW, and Mayo Clinic Cohorts
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Association of EZH2 and Survival in TCGA, UTSW, and Mayo Clinic Cohorts

![](JCO.2017.73.3238t2)

Correlation Between EZH2 mRNA Expression and EZH2 IHC Staining in RCC Tumor Grafts {#s10}
----------------------------------------------------------------------------------

Given the availability of IHC platforms in clinical laboratories, we next evaluated the correlation between *EZH2* mRNA and protein expression, leveraging 23 RCC tumorgraft samples for which we published RNA-seq results (n = 9).^[@B16]^ We optimized an EZH2 IHC assay in FFPE using an antibody validated for in vitro diagnostic use.^[@B13]^ A genitourinary pathologist blinded to the clinical results and RNA sequencing data recorded the percentages of positive tumor nuclei in the entire section. As expected, EZH2 had a nuclear expression pattern ([Figs 1A and 1B](#F1){ref-type="fig"}). Benign kidney was negative. We observed a correlation between *EZH2* mRNA expression and IHC intensity (Pearson correlation, 0.60; Appendix [Fig A1](#FA.1){ref-type="fig"}, online only) in 23 samples from published tumorgrafts.^[@B16]^

![Enhancer of zeste homolog 2 (EZH2) immunohistochemical staining and Kaplan-Meier estimate of overall survival in independent analytic and validation cohorts. Representative images for EZH2 staining: (A) negative (≤ 8.7%) and (B) positive (\> 8.7%) in renal cell carcinoma. Scale bar, 100 μM. (Original magnification, ×200; inset of representative nuclei, ×400.) Overall survival by EZH2 expression in (C) analytic and (D) validation cohorts.](JCO.2017.73.3238f1){#F1}

Clinicopathologic Characteristics of Analytic (UTSW) and Validation (Mayo Clinic) Cohorts {#s11}
-----------------------------------------------------------------------------------------

We next evaluated the association of EZH2 protein expression and survival using two cohorts. In the UTSW cohort, 57% of patients were male, the median age was 62 years, the median tumor size was 5.9 cm, and 53% of the tumors had low-risk SSIGN scores ([Table 1](#T1){ref-type="table"}). Of the 1,360 patients evaluated in the Mayo cohort, 1,338 (98.4%) were analyzed by EZH2 IHC (Appendix [Fig A2](#FA.2){ref-type="fig"}, online only). In the Mayo Clinic cohort, 66% of patients were male, the median age was 64 years, the median tumor size was 5.0 cm, and 65% of the tumors had low-risk SSIGN scores ([Table 1](#T1){ref-type="table"}). In both cohorts, EZH2-high expression was associated with increased tumor size, higher TNM stage, higher tumor grade, presence of necrosis, and sarcomatoid de-differentiation (Appendix [Tables A2](#TA.2){ref-type="table"} and [A3](#TA.3){ref-type="table"}, online only).

Association of EZH2 and Clinical Outcomes (UTSW cohort) {#s12}
-------------------------------------------------------

To examine the association between EZH2 protein expression by IHC (average percentage of cells staining across the entire slide) and overall survival, we modeled EZH2 expression as a continuous and dichotomous variable. Continuous EZH2 protein expression was significantly associated with overall survival after adjusting for age (HR, 1.66; 95% CI, 1.26 to 2.18; *P* = .0003; [Table 2](#T2){ref-type="table"}). When modeled as a dichotomized variable, patients with EZH2-high protein expression were 2.67 times more likely to experience death than patients with EZH2-low expression (95% CI, 1.33 to 5.38; *P* = .006) after adjusting for age ([Fig 1C](#F1){ref-type="fig"}). After adjustment for age and SSIGN, patients with EZH2-high protein expression were 2.16 times more likely to experience death than patients with EZH2-low expression (95% CI, 1.06 to 4.42; *P* = .034). The prognostic performance of EZH2 was evaluated at 1, 2, 5, 10, and 15 years of follow-up using time-dependent receiver operating characteristic curves (Appendix [Fig A3A](#FA.3){ref-type="fig"}, online only); the AUC ranged from 0.69 to 0.75.

Association of EZH2 and Clinical Outcomes (Mayo cohort) {#s13}
-------------------------------------------------------

To validate the association between EZH2 protein expression and overall survival, we evaluated EZH2 expression in an independent cohort. After adjusting for age, continuous EZH2 protein expression was significantly associated with overall survival (HR, 1.68; 95% CI, 1.54 to 1.85; *P* \< .001; [Table 2](#T2){ref-type="table"}). When modeled as a dichotomized variable, patients with EZH2-high protein expression were 2.45 times more likely to experience death than patients with EZH2-low expression (95% CI, 2.08 to 2.90; *P* \< .001) after adjusting for age ([Fig 1D](#F1){ref-type="fig"}). After adjusting for age and SSIGN, patients with EZH2-high protein expression were 1.43 times more likely to experience death than patients with EZH2-low expression (95% CI, 1.18 to 1.73; *P* = .00026). The addition of EZH2 expression to a model with SSIGN and age improved the C-index to 0.745, from 0.689 for SSIGN alone and 0.740 for SSIGN and age ([Table 2](#T2){ref-type="table"} and Appendix [Table A1](#TA.1){ref-type="table"}). The AUC at 1, 2, 5, 10, and 15 years of follow-up ranged from 0.79 to 0.90 (Appendix [Fig A3B](#FA.3){ref-type="fig"}).

To follow Reporting Recommendations for Tumor Marker Prognostic Studies guidelines,^[@B17]^ we next examined the effect of dichotomized EZH2 protein expression in the context of RCC-specific survival and standard clinicopathologic variables. After adjusting for age, SSIGN score--classified low-risk patients with high EZH2 protein expression were 6.14 times more likely to experience RCC-specific death than patients with EZH2-low tumors (HR, 6.14; 95% CI, 3.40 to 11.08; *P* \< .001; [Fig 2A](#F2){ref-type="fig"}, [Table 3](#T3){ref-type="table"}). Similarly, among patients with intermediate-risk SSIGN tumors, patients with high EZH2 protein expression were 2.12 times more likely to experience RCC-specific death (95% CI, 1.54 to 2.92; *P* \< .001). We did not observe a significant association among high-risk SSIGN tumors (*P* = .27).

![Kaplan-Meier estimate of overall survival (OS) by dichotomized enhancer of zeste homolog 2 (EZH2) expression in patients stratified by Mayo stage, size, grade, and necrosis (SSIGN) scores. (A) low-risk, (B) intermediate-risk, and (C) high-risk scores.](JCO.2017.73.3238f2){#F2}
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Association of EZH2 Protein Expression and Survival in Mayo Clinic Cohort, Stratified by SSIGN Risk Categories
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Comparison of EZH2 IHC Staining Quantitation Between Two Visual Scoring Methods As Well As With a Computer-Assisted Digital Image Analysis {#s14}
------------------------------------------------------------------------------------------------------------------------------------------

Using the Mayo cohort, we first compared the Cox model results using the average visual percentage of cells staining across the entire slide and the average visual percentage of staining in any single ×10 field. As shown in Appendix [Table A4](#TA.4){ref-type="table"} (online only), the hazard rates are similar across the two visual scoring methods. Similarly, we ran the Cox models using the Aperio digital quantification. The quantification was highly correlated with the average visual percentage of cells staining across the entire slide (Pearson correlation = 0.88; Appendix [Fig A4A](#FA.4){ref-type="fig"}, online only). Similarly, the quantification was highly correlated with the highest visual percentage of staining in a single 10× field (Pearson correlation = 0.86; Appendix [Fig A4B](#FA.4){ref-type="fig"}). The Cox model hazard rates for the Aperio quantification are provided in Appendix [Table A5](#TA.5){ref-type="table"} (online only).

DISCUSSION {#s15}
==========

Although preclinical models implicate EZH2 in tumorigenesis, there are conflicting results in the literature regarding the prognostic effect of EZH2 protein expression on the outcomes of patients with RCC.^[@B5],[@B6],[@B18]-[@B22]^ Indeed, some authors report that increased EZH2 expression is associated with a lower risk of recurrence, whereas others report an association with a higher risk of death following surgery for RCC.^[@B5],[@B6]^ One explanation for these contrasting observations is that differences in EZH2 antibody epitopes may influence EZH2 detection and quantitation. To improve on this, we used an antibody that is already validated for in vitro diagnostics. Furthermore, the prior studies were limited by a small sample size (ie, \< 200 patients) and failed to adjust for clinicopathologic factors associated with RCC outcome. In our study, we included three independent cohorts (total of 1,992 tumors) with centralized pathology review to report that EZH2 expression is associated with higher risk of poor outcome following surgery, in a univariate setting, and after adjusting for clinicopathologic prognostic factors. Our observations using a single-slide IHC assay in ccRCC include the following: (1) concordance of EZH2 IHC expression data between a digital Aperio and pathologist visual scoring; (2) an association between increased EZH2 expression and poor outcomes (overall survival) in three independent cohorts, even after adjusting for the Mayo SSIGN score; and (3) EZH2 protein expression can further stratify patients into prognostic groups within both low- and intermediate-risk patients (as defined by the SSIGN score).

The association of higher tumor-based EZH2 protein expression with a greater risk of RCC-specific death suggests a link between EZH2 and tumor progression. Related to this, increased EZH2 expression is mechanistically associated with loss of tumor suppressors (p27^KIP1^) and tumor invasion.^[@B19],[@B20],[@B22]^ Of clinical interest, in contrast to the 3p chromatin remodelers that are challenging to therapeutically target given the loss of function, an increase in EZH2 enzymatic activity could be directly targeted with EZH2 inhibitors such as tazemetostat^[@B23]^ or CPI-1205.^[@B24]^

Although our study was designed to address limitations of previous investigations, there are limitations of our own work that should be considered. First, we evaluated EZH2 expression in tissue microarrays (analytic cohort) and whole slides (validation cohort). Related to this, intratumor heterogeneity occurs in RCC, and prognostic biomarkers may be influenced by tumor sampling or inter-rater variability.^[@B25],[@B26]^ We used the Aperio platform to systematically assess EZH2 staining and found that the results had a high correlation with pathologist scoring. Furthermore, EZH2 protein expression in both the whole slide and a single ×10 field was associated with a higher risk of death. Second, the median duration of follow-up in the analytic cohort was relatively short, at 5.8 years (range, 0.0 to 15.7 years). By comparison, for the validation cohort, the median duration of follow-up was 8.8 years (range, 0.01 to 21.1 years). Finally, from a purely prognostic standpoint, the positive association of higher EZH2 expression with risk of poor outcome was attenuated among high-risk SSIGN score ≥ 8 tumors, suggesting that adverse pathologic variables are already a strong predictor of poor outcomes. This is logical, given that the pathology-based SSIGN score is a surrogate measure for the underlying molecular mechanisms that drive tumor progression. Therefore, the importance of our findings is underscored by the fact that they support EZH2 as a target (and potentially a companion biomarker) for novel therapeutic approaches to improve outcomes of patients with RCC.

Authors of two prior studies, A 16-Gene Assay to Predict Recurrence After Surgery in Localised Renal Cell Carcinoma^[@B27]^ (Recurrence Score), and A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma^[@B28]^ (ClearCode34), have evaluated prognostic RNA expression signatures. The Recurrence Score is associated with a three-fold increase in risk of recurrence. Similarly, ClearCode34 subtypes are associated with a two-fold increase in risk of recurrence. The importance of these pioneering observations notwithstanding, RNA-based assays may be affected by selection bias because larger amounts of RNA are required for the assay, necessitating access to larger tumors and potentially biasing results away from smaller ones. Indeed, a 20.2% failure rate for adequate RNA yield/assay performance was reported in the ClearCode34 study. In contrast, the EZH2 IHC assay uses a monoclonal antibody validated for in vitro diagnostics, requires only a single slide (1.6% assay failure rate), and is compatible with an imaging platform that is available in clinical laboratories.

The rise in RCC incidence over the past three decades, particularly of small (≤ 4 cm) tumors, can be partially attributed to the widespread use of imaging.^[@B29]^ Despite adherence to surveillance guidelines, one-third of patients with RCC experience disease progression following surgery, underscoring the need to identify patients with a higher risk of recurrence, particularly those with smaller tumors.^[@B9]^ Of note, the design of two adjuvant RCC trials, A Clinical Trial Comparing Efficacy and Safety of Sunitinib Versus Placebo for the Treatment of Patients at High Risk of Recurrent Renal Cell Cancer^[@B30]^ (*S*-TRAC), and ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma^[@B31]^ (ECOG-ACRIN E2805) incorporate clinicopathologic models to identify high-risk patients, but do not incorporate molecular alterations. Moreover, although subsets of patients with RCC are excluded from adjuvant studies because their tumors would be stratified as low risk, we show that patients classified as low risk by the SSIGN score who have EZH2-high expression are six times more likely to die of RCC compared with patients with EZH2-low expression. Thus, there is an opportunity to leverage this biomarker to design more robust clinical trials that are focused on those patients with aggressive disease.

In conclusion, in this study, we validated the association between increased EZH2 expression and a higher risk of death in three independent cohorts after adjusting for the SSIGN score. The association is particularly significant in patients classified as low or intermediate risk by the SSIGN score. With the increasing incidence of small RCC tumors detected by cross-sectional imaging, our study emphasizes the clinical utility of a biomarker that is compatible with a single FFPE slide that accurately predicts risk of RCC death beyond existing clinicopathologic models. Further studies are required to determine how to better incorporate molecular biomarkers with prognostic information into surveillance guidelines and adjuvant clinical trials.
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METHODS
=======

Analysis of Enhancer of Zeste Homolog 2 mRNA Expression in The Cancer Genome Atlas Data Set {#s32}
-------------------------------------------------------------------------------------------

The Cancer Genome Atlas kidney renal clear cell carcinoma RNA sequencing level 3 data (expectation-maximization normalized data) were downloaded from Broad GDAC Firehose (<https://confluence.broadinstitute.org/display/GDAC/Home>). The clinical data were downloaded from The Cancer Genome Atlas on May 19, 2017 (<https://tcga-data.nci.nih.gov/tcga/>).

Analysis of Enhancer of Zeste Homolog 2 mRNA in Tumorgrafts {#s33}
-----------------------------------------------------------

To determine if enhancer of zeste homolog 2 (EZH2) RNA levels identified from RNA-seq analysis translate to protein changes, we conducted a pilot EZH2 immunohistochemistry analysis on 23 University of Texas Southwestern Medical Center samples from renal cell carcinoma tumorgrafts. RNA sequencing data are available at the Sequence Read Archive (SRP073253).

![Correlation between enhancer of zeste homolog 2 immunohistochemistry (IHC) protein analysis and enhancer of zeste homolog 2 mRNA expression by RNA sequencing (RNA-Seq).](JCO.2017.73.3238app1){#FA.1}

![Flow diagram of enhancer of zeste homolog 2 (EZH2) immunohistochemistry analysis in the analytic and validation cohorts. UTSW, University of Texas Southwestern Medical Center.](JCO.2017.73.3238app2){#FA.2}

![Time-dependent receiver operating characteristic curve with regard to enhancer of zeste homolog 2 expression for (A) analytic and (B) validation cohorts. AUC, area under the curve.](JCO.2017.73.3238app3){#FA.3}

![Correlation of enhancer of zeste homolog 2 (EZH2) immunohistochemical staining quantitation between digital image analysis and pathologist visual scoring in the validation cohort. (A) Analysis of average percentage of cells staining positive for EZH2 across an entire slide. (B) Analysis of average percentage of cells staining positive for EZH2 in a single ×10 field. The dotted line represents equality.](JCO.2017.73.3238app4){#FA.4}
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Association of Age and SSIGN With Survival
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Clinical Characteristics of University of Texas Southwestern Medical Center Cohort by Dichotomized EZH2 Expression
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Clinical Characteristics of Mayo Clinic Cohort by Dichotomized EZH2 Expression
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Association of Continuous EZH2 Protein Expression With Outcome in the Validation (Mayo Clinic) Cohort for Two Different Visual Scoring Methods
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Association of EZH2 Protein Expression With Outcome in the Validation (Mayo Clinic) Cohort Using Digital (Aperio) Image Analysis
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